Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Relapsed or Refractory Multiple Myeloma
Clinical trial register · United States · industry-sponsored

Relapsed or Refractory Multiple Myeloma Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9144 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 16 Oct 2026, 03:16 UTC
9144
Studies in scope
industry-sponsored, all four open statuses
4957
Recruiting now
open to new participants
2196
Lead sponsors
across recruiting studies
Top states
California 8 Florida 6 Colorado 5 Georgia 5 Massachusetts 4
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Relapsed or Refractory Multiple Myeloma trials in the USA

8 of 9144 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
AbbVie
Phase 3
520
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Massachusetts
2026-11-30
Recruiting
AstraZeneca
Phase 1/2
101
California, Colorado, Florida, Georgia, Missouri, New Jersey, Ohio, Tennessee
2026-07-27
Recruiting
ModernaTX, Inc.
Phase 1/2
190
Alabama, California, Georgia, Massachusetts, New York, North Carolina, Pennsylvania, Tennessee
2025-09-30
Recruiting
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
130
Arizona, California, Florida, Massachusetts, Minnesota, New York, North Carolina, Tennessee
2024-05-24
Active, closed
Janssen Research & Development, LLC
Phase 3
614
Alaska, Arizona, California, Colorado, Connecticut, Florida, Iowa, Louisiana
2023-03-29
Active, closed
Bristol-Myers Squibb
Phase 3
606
Alabama, California, Florida, Georgia, Idaho, Maryland, Massachusetts, Minnesota
2023-01-10
Recruiting
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
NCT05652335Relapsed or Refractory Multiple Myeloma, Previously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC
Phase 1
180
California, Colorado, New York, North Carolina, Pennsylvania, Texas
2022-11-22
Recruiting
Celgene
Phase 3
810
California, Colorado, Connecticut, Florida, Georgia, Kansas, Louisiana, Maryland
2022-09-20
Rows per page Showing 1–8 of 8
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 16 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/relapsed-or-refractory-multiple-myeloma

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,144 studies in total at the last sync on 16 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 8 of those studies listing the condition Relapsed or Refractory Multiple Myeloma.

How many Relapsed or Refractory Multiple Myeloma trials are recruiting in the US?

5 of the 8 studies on this page are recruiting new participants as of the 16 Oct 2026, 03:16 UTC sync. A further 1 have not yet opened recruitment, 2 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Relapsed or Refractory Multiple Myeloma), 8 studies
PhaseStudiesRecruitingShare
Phase 34150%
Phase 12225%
Phase 1/22225%

Most active sponsors

Lead sponsors with the most studies (Relapsed or Refractory Multiple Myeloma)
Lead sponsorStudiesRecruiting
Janssen Research & Development, LLC21
AbbVie10
AstraZeneca11
Bristol-Myers Squibb10
Celgene11
Jiangsu Simcere Pharmaceutical Co., Ltd.11
ModernaTX, Inc.11

Top states

Top states (Relapsed or Refractory Multiple Myeloma), by number of studies with a site there
StateStudies
California8
Florida6
Colorado5
Georgia5
Massachusetts4
Arizona3
New York3
North Carolina3
Tennessee3
Alabama2
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.